Bioventus Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 28/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bioventus Inc's Score
Industry at a Glance
Industry Ranking
28 / 207
Overall Ranking
108 / 4563
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
15.000
Target Price
+108.62%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Bioventus Inc Highlights
StrengthsRisks
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Overvalued
The company’s latest PE is 47.61, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 49.87M shares, decreasing 0.00% quarter-over-quarter.
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Ticker SymbolBVS
CompanyBioventus Inc
CEOClaypoole (Robert E)
Websitehttps://www.bioventus.com/
FAQs
What is the current price of Bioventus Inc (BVS)?
The current price of Bioventus Inc (BVS) is 7.460.
What is the symbol of Bioventus Inc?
The ticker symbol of Bioventus Inc is BVS.
What is the 52-week high of Bioventus Inc?
The 52-week high of Bioventus Inc is 11.250.
What is the 52-week low of Bioventus Inc?
The 52-week low of Bioventus Inc is 5.810.
What is the market capitalization of Bioventus Inc?
The market capitalization of Bioventus Inc is 499.62M.
What is the net income of Bioventus Inc?
The net income of Bioventus Inc is -33.54M.
Is Bioventus Inc (BVS) currently rated as Buy, Hold, or Sell?
According to analysts, Bioventus Inc (BVS) has an overall rating of Buy, with a price target of 15.000.
What is the Earnings Per Share (EPS TTM) of Bioventus Inc (BVS)?
The Earnings Per Share (EPS TTM) of Bioventus Inc (BVS) is 0.157.